Lantheus (NASDAQ:LNTH) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday.

Other equities research analysts have also issued research reports about the company. Jefferies Group boosted their price target on Lantheus from $22.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. ValuEngine lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday. Zacks Investment Research lowered Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 9th. Credit Suisse Group boosted their price target on Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Finally, Wells Fargo & Company upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $24.50.

Shares of Lantheus (NASDAQ LNTH) opened at $20.75 on Tuesday. Lantheus has a 52 week low of $7.95 and a 52 week high of $24.10. The firm has a market capitalization of $778.25 and a PE ratio of 19.51. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.04. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The business had revenue of $79.94 million for the quarter, compared to analyst estimates of $77.18 million. During the same quarter in the previous year, the firm earned $0.15 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. research analysts forecast that Lantheus will post 1.05 EPS for the current fiscal year.

In related news, insider Michael P. Duffy sold 11,917 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $21.63, for a total value of $257,764.71. Following the sale, the insider now owns 152,301 shares in the company, valued at $3,294,270.63. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David F. Burgstahler sold 78,833 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $16.95, for a total value of $1,336,219.35. Following the completion of the sale, the director now owns 13,248 shares in the company, valued at approximately $224,553.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 246,777 shares of company stock worth $4,258,192. 2.30% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. State of Alaska Department of Revenue purchased a new stake in Lantheus in the second quarter valued at approximately $102,000. Municipal Employees Retirement System of Michigan acquired a new position in Lantheus in the second quarter valued at approximately $107,000. LS Investment Advisors LLC acquired a new position in Lantheus in the second quarter valued at approximately $112,000. Quantbot Technologies LP acquired a new position in Lantheus in the second quarter valued at approximately $117,000. Finally, Sei Investments Co. lifted its holdings in Lantheus by 189.6% in the third quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock valued at $139,000 after acquiring an additional 5,126 shares during the period. Hedge funds and other institutional investors own 91.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Lantheus (LNTH) Downgraded by BidaskClub” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/12/04/lantheus-lnth-downgraded-by-bidaskclub.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.